Equities analysts forecast that VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Rating) will report earnings of ($0.15) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for VYNE Therapeutics’ earnings. VYNE Therapeutics posted earnings per share of ($0.37) during the same quarter last year, which would suggest a positive year-over-year growth rate of 59.5%. The company is expected to issue its next earnings results on Monday, January 1st.
On average, analysts expect that VYNE Therapeutics will report full year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.72) to ($0.53). For the next year, analysts anticipate that the business will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.73) to ($0.37). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for VYNE Therapeutics.
VYNE Therapeutics (NASDAQ:VYNE – Get Rating) last announced its quarterly earnings results on Thursday, March 17th. The company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.05. VYNE Therapeutics had a negative return on equity of 106.54% and a negative net margin of 496.98%.
Shares of VYNE stock opened at $0.49 on Wednesday. The business’s 50-day moving average price is $0.59 and its 200-day moving average price is $0.89. VYNE Therapeutics has a 12 month low of $0.46 and a 12 month high of $5.47. The firm has a market capitalization of $27.72 million, a price-to-earnings ratio of -0.34 and a beta of 0.96.
Institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its holdings in VYNE Therapeutics by 175.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 115,698 shares of the company’s stock worth $118,000 after purchasing an additional 73,642 shares in the last quarter. Virtu Financial LLC increased its holdings in VYNE Therapeutics by 61.8% in the fourth quarter. Virtu Financial LLC now owns 175,278 shares of the company’s stock worth $179,000 after purchasing an additional 66,959 shares in the last quarter. Susquehanna International Group LLP increased its holdings in VYNE Therapeutics by 217.1% in the fourth quarter. Susquehanna International Group LLP now owns 45,330 shares of the company’s stock worth $46,000 after purchasing an additional 31,033 shares in the last quarter. Marshall Wace LLP bought a new stake in VYNE Therapeutics in the fourth quarter worth approximately $169,000. Finally, DSC Advisors L.P. increased its holdings in VYNE Therapeutics by 131.9% in the fourth quarter. DSC Advisors L.P. now owns 2,551,000 shares of the company’s stock worth $2,602,000 after purchasing an additional 1,451,000 shares in the last quarter. 26.73% of the stock is currently owned by institutional investors.
VYNE Therapeutics Company Profile (Get Rating)
VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis.
- Get a free copy of the StockNews.com research report on VYNE Therapeutics (VYNE)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.